Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

@article{Stohl2012BelimumabRA,
  title={Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.},
  author={William Stohl and Falk Hiepe and Kevin M. Latinis and Mathew Thomas and Morton Aaron Scheinberg and Ann Clarke and Cynthia Aranow and Frank R Wellborne and Carlos Abud-Mendoza and Douglas R Hough and Lilia Pineda and T Migone and Z John Zhong and William W Freimuth and W. Winn Chatham},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 7},
  pages={2328-37}
}
OBJECTIVE To assess the effects of the B lymphocyte stimulator (BLyS)-specific inhibitor belimumab on immunologic biomarkers, including B cell and T cell populations, and maintenance of antibody titers to prior vaccines in autoantibody-positive systemic lupus erythematosus (SLE) patients. METHODS Pooled data from 2 phase III trials, the Study of Belimumab in Subjects with SLE 52-week (BLISS-52) and 76-week (BLISS-76) trials, comparing belimumab 1 mg/kg or 10 mg/kg versus placebo (plus… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
84 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 84 extracted citations

Similar Papers

Loading similar papers…